REGICOR mejor que Framingham en el cálculo del riesgo coronario: una buena noticia para nuestros pacientes

Sánchez Pérez, Ricard.
Med. clín (Ed. impr.) ; 122(15): 597-598, abr. 2004.
Artículo en Es | IBECS (España) | ID: ibc-32040

Documentos relacionados

  1. Molecular Insights into Site-Specific Interferon-α2a Bioconjugates Originated from PEG, LPG, and PEtOx.
  2. Interferon-alpha 2a injections for extensive multiple planar viral acanthomas - a potential new therapeutic approach.
  3. Separating antibody species containing one and two kappa light chain constant region by KappaSelect affinity chromatography.
  4. Novel long-acting ropeginterferon alfa-2b: Pharmacokinetics, pharmacodynamics and safety in a phase I clinical trial.
  5. Serum Free Light Chain Reference Intervals in a Local Population in Spain using the Optilite Analyser.
  6. Polymer selection impacts the pharmaceutical profile of site-specifically conjugated Interferon-α2a.
  7. Exposure-efficacy and exposure-safety analyses of ropeginterferon alfa-2b treatment in patients with polycythaemia vera.
  8. [Multiple myeloma with double gammopathy (IgA-kappa, IgA-lambda) : induction of complete remission from plateau phase with interferon-alpha 2a therapy].
  9. Reference Intervals for Plasma Free Kappa and Lambda Chains and Kappa/Lambda Ratio using PENIA.
  10. Utilizing Mass Spectrometry to Detect and Isotype Monoclonal Proteins in Urine: Comparison to Electrophoretic Methods.